Wired Magazine reports that drug companies’ are facing a new obstacle in clinical trials: over the past few decades, the placebo response has gotten stronger. Some drugs, like Prozac, would have had trouble getting FDA approval if their effectiveness against placebos were as insignificant as tests now show.
